2006
DOI: 10.1200/jco.2005.04.9130
|View full text |Cite
|
Sign up to set email alerts
|

Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Abstract: A B S T R A C T PurposeHepatocellular carcinoma (HCC) is a vascular tumor with poor prognosis. Given the reported activity of gemcitabine and oxaliplatin (GEMOX) in HCC and the potential benefits of targeting the vascular endothelial growth factor pathway with bevacizumab (B), a phase II study of GEMOX-B was undertaken to define efficacy and toxicity profiles in HCC patients. Patients and MethodsEligible patients had pathologically proven measurable unresectable or metastatic HCC. For cycle 1 (14 days), bevaci… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
233
1
7

Year Published

2008
2008
2017
2017

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 357 publications
(245 citation statements)
references
References 33 publications
4
233
1
7
Order By: Relevance
“…These results should be interpreted with caution because a sorafenib-alone arm was not included and high incidence of adverse events related to doxorubicin was noted. Many small-scale trials of combining MTT with cytotoxic chemotherapy have been reported [385][386][387][388][389]. However, the treatment efficacy in terms of tumor response rate and patient survival were similar to those reported for the cytotoxic regimens alone (Table 3) [372,[375][376][377][378][379][380][381][382].…”
Section: Future Directionsmentioning
confidence: 54%
“…These results should be interpreted with caution because a sorafenib-alone arm was not included and high incidence of adverse events related to doxorubicin was noted. Many small-scale trials of combining MTT with cytotoxic chemotherapy have been reported [385][386][387][388][389]. However, the treatment efficacy in terms of tumor response rate and patient survival were similar to those reported for the cytotoxic regimens alone (Table 3) [372,[375][376][377][378][379][380][381][382].…”
Section: Future Directionsmentioning
confidence: 54%
“…An anti-VEGF monoclonal antibody has been approved for treatment of cancer patients [38] . Promising results that use the anti-VEGF antibody in combination with systemic chemotherapy in treating advanced HCC have recently been reported [39] . Furthermore, several VEGF receptor antagonists currently in clinical trials have been shown to inhibit growth and metastasis of HCC in preclinical studies [24] .…”
Section: Discussionmentioning
confidence: 99%
“…Poor liver function was commonly identified as an adverse prognostic factor in previous studies [34][35][36][37][38][39] . However, as shown in this study, tumor progression including vascular invasion, extrahepatic metastasis and advanced BCLC stage rather than liver failure was the main adverse prognostic factor after TACE.…”
Section: Discussionmentioning
confidence: 99%
“…Combination treatment of bevacizumab with EGFR targeting agents was shown to be safe and revealed promising initial results with a median time to progression of 9 months (Thomas et al, 2007b) (see Table 1). Overall, bevacizumab has shown promising results as a single agent as well as in combination with other targeted therapies and cytotoxic therapy (Zhu et al, 2006) supporting the idea of a vascular targeting therapy for the treatment of HCC.…”
Section: Results From Phase I and Ii Studies Testing Other Approved Tmentioning
confidence: 96%